BRAND_ANALYSIS#ILLUMINAHEALTH & PHARMA#14 OF 26 IN HEALTH & PHARMAALIGNED
Illumina
· Public · Updated 22 Nov 2026 07:19 UTC
#395 of 1208 overall by tension · #14 of 26 in Health & Pharma
12Aligned
The Balanced
Analysis
Illumina sequences the genome for clinics and researchers, and C=40 with B=52 reflects a company whose science matters enormously to a small world and very little to the public. A -28.43% stock drop over 30 days shows investors punishing the sector's uncertainty. At #395, the most important biotech tool in the room is also the most financially bruised.
IN THE NEWS (34 articles this week)
Introducing the CellularAI algorithm: Predicting single-cell responses to genetic perturbations - Illumina
Illumina announces layoffs at San Diego headquarters - San Diego Union-Tribune
Illumina to Cut 51 Jobs at San Diego Headquarters - GenomeWeb